Vascular Access Devices Market Size, Share & Trends Analysis Report By Product (Short PIVCs, Huber Needles, Midline Catheters, PICCs, CVCs, Dialysis Catheters, Implantable Ports), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Vascular Access Devices Market Size, Share & Trends Analysis Report By Product (Short PIVCs, Huber Needles, Midline Catheters, PICCs, CVCs, Dialysis Catheters, Implantable Ports), By End Use, By Region, And Segment Forecasts, 2025 - 2030


Vascular Access Devices Market Growth & Trends

The global vascular access devices market size is expected to reach USD 11.49 billion in 2030 and is anticipated to grow at a CAGR of 4.7% during the forecast from 2025 to 2030. The rise in the geriatric population, the prevalence of chronic illnesses, and the number of surgical operations all contribute to the market's expansion. The vascular system could be accessed with vascular access devices such that fluids, drugs, and blood can be administered or removed. For the treatment of severe medical illnesses including cancer and renal failure, these devices are frequently employed. The need for vascular access devices is anticipated to be driven by the rising prevalence of chronic disorders. Additionally, technological advancements in medical devices are also likely to support the growth of the market.

An increase in chronic illnesses including cancer, renal disease, heart disease, hypertension, diabetes, obesity, and depression has led to an increase in new cases of cancer. For instance, the GLOBOCAN 2020 report states that 19,292,789 new cancer cases were reported in 2020, out of which 2,261,419 and 2,206,771 were specifically related to breast cancer and lung cancer, respectively. Additionally, according to WHO data released in April 2021, chronic illnesses would cause the deaths of 41 million people per year (71% of all fatalities), with 77% of those deaths occurring in low- and middle-income countries. The demand for vascular access devices would be rising as cancer rates grow in the coming years.

Key players in the market are investing in the launch of new products and collaborations for sustaining their market presence. For instance, in September 2022, Access Vascular, Inc., partnered with the Association for Vascular Access (AVA). This partnership aims to enhance patient outcomes with evidence-based practices and tech education. Moreover, in May 2020, Smiths Medical (ICU Medical, Inc.) acquired Access Scientific, LLC's business; this transaction extends Smiths Medical’s vascular access product portfolio.

Vascular Access Devices Market Report Highlights
  • On the basis of product, the market is divided into Short Peripheral Intravenous Catheter (Short PIVCs), Huber Needles, Midline Catheters, Peripherally Inserted Central Catheter (PICCs), Dialysis Catheters, Implantable Ports, and Central venous catheters. Furthermore, the Short Peripheral Intravenous Catheter (Short PIVCs) segment accounted for the largest market share of over 44% in 2024 and is expected to maintain its dominance over the forecast period. This is attributed to the increasing number of emergency surgeries and the rising prevalence of chronic diseases
  • The market is further segmented on the basis of end-users, which includes hospitals, ambulatory surgical centers, and other end-users. Hospitals accounted for the largest market share in 2024 and are expected to maintain their dominance over the forecast period. This is attributed to the presence of well-equipped healthcare facilities, high healthcare expenditure, and the availability of skilled healthcare professionals in hospitals
  • North America held a major market share of over 53.35% in 2024; this is attributed to the presence of advanced healthcare infrastructure and the rising prevalence of chronic diseases in the regio
  • The competitive landscape for vascular access devices is highly competitive, with many companies offering different types of products and services. The major players in this market include BD, B. Braun Melsungen AG, Terumo Corporation, Teleflex Incorporated, and Smiths Medical. These companies are continuously innovating and introducing new products and services to maintain their market share. Other smaller companies such as AngioDynamics, Deltamed, and Merit Medical Systems have a presence in the market
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Recombinant Proteins Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Host Cell Segment
1.2.3. Application Segment
1.2.4. End-use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
Chapter 2. Recombinant Proteins Market: Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Recombinant Proteins Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.2.1. Market Dynamics
3.2.1.1. Increasing Investments In Research & Development Activities
3.2.1.2. Growing research activities for drug discovery and precision medicine
3.2.1.3. Rising adoption of biologics & biosimilars
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory and safety concerns regarding protein production
3.2.2.2. Dearth of skilled personnel and expertise
3.3. Business Environment Analysis
3.3.1. PESTEL Analysis
3.3.2. Porter’s Five Forces Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Product Segment Dashboard
4.2. Recombinant Proteins Market: Product Movement Analysis
4.3. Global Recombinant Proteins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Cytokines & Growth Factors
4.4.1. Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
4.4.2. Interferons (IFNs)
4.4.2.1. Interferons (IFNs) Market, 2018 - 2030 (USD Million)
4.4.3. Interleukins (ILs)
4.4.3.1. Interleukins (ILs) Market, 2018 - 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others Market, 2018 - 2030 (USD Million)
4.5. Antibodies
4.5.1. Antibodies, 2018 - 2030 (USD Million)
4.6. Immune Checkpoint Proteins
4.6.1. Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
4.7. Virus Antigens
4.7.1. Virus Antigens Market, 2018 - 2030 (USD Million)
4.8. Enzymes
4.8.1. Enzymes Market, 2018 - 2030 (USD Million)
4.8.2. Kinases
4.8.2.1. Kinases Market, 2018 - 2030 (USD Million)
4.8.3. Metabolic Enzymes
4.8.3.1. Metabolic Enzymes Market, 2018 - 2030 (USD Million)
4.8.4. Others
4.8.4.1. Others Market, 2018 - 2030 (USD Million)
4.9. Recombinant Regulatory Proteins
4.9.1. Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
4.10. Hormones
4.10.1. Hormones Market, 2018 - 2030 (USD Million)
4.11. Others
4.11.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Host Cell Business Analysis
5.1. Host Cell Segment Dashboard
5.2. Recombinant Proteins Market: Host Cell Movement Analysis
5.3. Global Recombinant Proteins Market Size & Trend Analysis, by Host Cell, 2018 to 2030 (USD Million)
5.4. Mammalian Cells
5.4.1. Mammalian Cells Market, 2018 - 2030 (USD Million)
5.5. Bacterial Cells
5.5.1. Bacterial Cells Market, 2018 - 2030 (USD Million)
5.6. Yeast & Fungi
5.6.1. Yeast & Fungi Market, 2018 - 2030 (USD Million)
5.7. Insect Cells
5.7.1. Insect Cells Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Application Segment Dashboard
6.2. Recombinant Proteins Market: Application Movement Analysis
6.3. Global Recombinant Proteins Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Drug Discovery & Development
6.4.1. Drug Discovery & Development Market, 2018 - 2030 (USD Million)
6.5. Therapeutics
6.5.1. Biologics
6.5.1.1. Biologics Market, 2018 - 2030 (USD Million)
6.5.2. Vaccines
6.5.2.1. Vaccines Market, 2018 - 2030 (USD Million)
6.5.3. Cell & Gene Therapies
6.5.3.1. Cell & Gene Therapies Market, 2018 - 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others Market, 2018 - 2030 (USD Million)
6.6. Research
6.6.1. Research Market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. End-use Business Analysis
7.1. End Use Segment Dashboard
7.2. Recombinant Proteins Market: End-use Movement Analysis
7.3. Global Recombinant Proteins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Pharmaceutical & Biotechnology Companies
7.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
7.5. Academic & Research Institutes
7.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Regional Dashboard
8.2. Global Market Share By Region, 2024 & 2030
8.3. North America
8.3.1. North America Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Scenario
8.3.2.4. U.S. Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Scenario
8.3.3.4. Canada Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4. Europe
8.4.1. Europe Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Scenario
8.4.2.4. UK Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Scenario
8.4.3.4. Germany Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.4. Spain
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Scenario
8.4.4.4. Spain Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.5. France
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Scenario
8.4.5.4. France Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.6. Italy
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Scenario
8.4.6.4. Italy Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Scenario
8.4.7.4. Denmark Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Scenario
8.4.8.4. Sweden Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Scenario
8.4.9.4. Norway Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Asia-Pacific Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Scenario
8.5.2.4. Japan Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Scenario
8.5.3.4. China Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Scenario
8.5.4.4. India Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Scenario
8.5.5.4. South Korea Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Scenario
8.5.6.4. Thailand Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.5.7. Australia
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Scenario
8.5.7.4. Australia Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.6. Latin America
8.6.1. Latin America Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Scenario
8.6.2.4. Brazil Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.6.3. Mexico
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Scenario
8.6.3.4. Mexico Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.6.4. Argentina
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Scenario
8.6.4.4. Argentina Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.7. MEA
8.7.1. MEA Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Scenario
8.7.2.4. South Africa Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Scenario
8.7.3.4. Saudi Arabia Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Scenario
8.7.4.4. UAE Recombinant Proteins Market, 2018 - 2030 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Scenario
8.7.5.4. Kuwait Recombinant Proteins Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific, Inc.
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Sino Biological, Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Benchmarking
9.4.2.3. Strategic Initiatives
9.4.3. GenScript
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Techne
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Proteintech Group, Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Benchmarking
9.4.5.3. Strategic Initiatives
9.4.6. Enzo Life Sciences, Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Benchmarking
9.4.6.3. Strategic Initiatives
9.4.7. Abnova Corp
9.4.7.1. Company Overview
9.4.7.2. Product Benchmarking
9.4.7.3. Strategic Initiatives
9.4.8. RayBiotech Life Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Benchmarking
9.4.8.3. Strategic Initiatives
9.4.9. STEMCELL Technologies Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Benchmarking
9.4.9.3. Strategic Initiatives
9.4.10. Bio-Rad Laboratories, Inc.
9.4.10.1. Company Overview
9.4.10.2. Product Benchmarking
9.4.10.3. Strategic Initiatives
9.4.11. Merck KGaA
9.4.11.1. Company Overview
9.4.11.2. Product Benchmarking
9.4.11.3. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings